Masters of Longevity Editorial
Filter by Article TypeEditorial
MoL Editorial • 07 Jul 2026 • 6 min readApoB: The cholesterol signal LDL can missBy Marcel AchermannIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.ApoBCardiovascular riskCholesterol
MoL Editorial • 25 Jun 2026 • 7 min readThe Next Obesity-Drug Race Is About What Weight You LoseBy Marcel AchermannRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.Regeneron PharmaceuticalsMyostatin inhibitorsActivin A inhibitors
MoL Editorial • 06 May 2026 • 7 min readFrom Metrics to Better LivingBy Marcel AchermannEverstride’s May 2026 Consumer Health Market Briefing shows a wellness market moving from products to systems, from tracking to guidance, and from optimization to meaning. The next winners in longevity may not be the companies that measure the most. They may be the ones that help consumers translate health data into a life they actually want to live.Market viewEverstride
MoL Editorial • 10 Apr 2026 • 5 min readA Global Rally for Life ExtensionBy José Luis CordeiroOn April 8, the streets of Madrid were not the scene of an ordinary protest. Citizens, scientists, entrepreneurs, and healthcare professionals gathered for the Longevity March, a global mobilization that connected Madrid simultaneously with major cities such as Brussels, London, Paris, and Berlin in Europe; Caracas, Mexico City, and San Francisco in the Americas; and Abu Dhabi and Tel Aviv in the Middle East, even during the current war in the region. The message was clear and urgent: aging must be treated as a global political and scientific priority.